SINCLAIR PHARMA FRANCE HOLDING : revenue, balance sheet and financial ratios

SINCLAIR PHARMA FRANCE HOLDING is a French company founded 20 years ago, specialized in the sector Activités des sociétés holding. Based in DARDILLY (69570), this company of category PME shows in 2024 a revenue of 38 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SINCLAIR PHARMA FRANCE HOLDING (SIREN 490245099)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue 37 705 € 31 372 € 41 100 € 46 406 € 64 140 € 229 719 € 139 007 € 299 764 € 1 766 906 €
Net income 1 539 € 1 198 € -77 336 € -4 268 035 € 1 491 766 € 5 925 271 € 1 226 448 € 296 894 € -6 597 002 €
EBITDA -64 236 € -7 138 € -21 144 € -16 644 € -42 437 € 142 389 € 7 578 € -620 611 € -3 732 264 €
Net margin 4.1% 3.8% -188.2% -9197.2% 2325.8% 2579.4% 882.3% 99.0% -373.4%

Revenue and income statement

In 2024, SINCLAIR PHARMA FRANCE HOLDING achieves revenue of 38 k€. Revenue is declining over the period 2016-2024 (CAGR: -38.2%). Vs 2023, growth of +20% (31 k€ -> 38 k€). After deducting consumption (0 €), gross margin stands at 38 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -64 k€, representing -170.4% of revenue. Warning negative scissor effect: despite revenue change (+20%), EBITDA varies by -800%, reducing margin by 147.6 pts. This reflects costs rising faster than revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 2 k€, i.e. 4.1% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

37 705 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

37 705 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-64 236 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

2 053 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

1 539 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

-170.4%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 37%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 73%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

36.512%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

72.924%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

-171.765%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

-79.017

Solvency indicators evolution
SINCLAIR PHARMA FRANCE HOLDING

Sector positioning

Debt ratio
36.51 2024
2022
2023
2024
Q1: 0.01
Med: 8.77
Q3: 62.6
Average +10 pts over 3 years

In 2024, the debt ratio of SINCLAIR PHARMA FRANCE HO... (36.51) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
72.92% 2024
2022
2023
2024
Q1: 15.71%
Med: 62.26%
Q3: 91.3%
Good -8 pts over 3 years

In 2024, the financial autonomy of SINCLAIR PHARMA FRANCE HO... (72.9%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
-79.02 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.09 years
Q3: 3.07 years
Excellent

In 2024, the repayment capacity of SINCLAIR PHARMA FRANCE HO... (-79.02) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 8528.71. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

8528.707

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

0.0

Liquidity indicators evolution
SINCLAIR PHARMA FRANCE HOLDING

Sector positioning

Liquidity ratio
8528.71 2024
2022
2023
2024
Q1: 138.65
Med: 681.09
Q3: 3914.52
Excellent

In 2024, the liquidity ratio of SINCLAIR PHARMA FRANCE HO... (8528.71) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
0.0x 2024
2022
2023
2024
Q1: -74.77x
Med: 0.0x
Q3: 0.0x
Good

In 2024, the interest coverage of SINCLAIR PHARMA FRANCE HO... (0.0x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 4202 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 254 days. The gap of 3948 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Overall, WCR represents 69082 days of revenue, i.e. 7.2 M€ to permanently finance. Over 2016-2024, WCR increased by +159%, requiring additional financing.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

7 235 399 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

4202 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

254 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

69082 j

WCR and payment terms evolution
SINCLAIR PHARMA FRANCE HOLDING

Positioning of SINCLAIR PHARMA FRANCE HOLDING in its sector

Comparison with sector Activités des sociétés holding

Valuation estimate

Based on 54 transactions of similar company sales in 2024, the value of SINCLAIR PHARMA FRANCE HOLDING is estimated at 14 218 € (range 8 859€ - 20 432€). The price/revenue ratio is 0.59x (in line with sector norms). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2024
54 tx
8k€ 14k€ 20k€
14 218 € Range: 8 859€ - 20 432€
NAF 5 année 2024

Valuation detail by method

Ajustez les pondérations selon votre analyse

Revenue Multiple 30%
37 705 € × 0.59x
Estimation 22 200 €
13 811€ - 26 391€
Net Income Multiple 20%
1 539 € × 1.5x
Estimation 2 247 €
1 433€ - 11 494€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Activités des sociétés holding)

Compare SINCLAIR PHARMA FRANCE HOLDING with other companies in the same sector:

Voir toutes les statistiques du secteur Activités des sociétés holding

Frequently asked questions about SINCLAIR PHARMA FRANCE HOLDING

What is the revenue of SINCLAIR PHARMA FRANCE HOLDING ?

The revenue of SINCLAIR PHARMA FRANCE HOLDING in 2024 is 38 k€.

Is SINCLAIR PHARMA FRANCE HOLDING profitable?

Yes, SINCLAIR PHARMA FRANCE HOLDING generated a net profit of 2 k€ in 2024.

Where is the headquarters of SINCLAIR PHARMA FRANCE HOLDING ?

The headquarters of SINCLAIR PHARMA FRANCE HOLDING is located in DARDILLY (69570), in the department Rhone.

Where to find the tax return of SINCLAIR PHARMA FRANCE HOLDING ?

The tax return of SINCLAIR PHARMA FRANCE HOLDING is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SINCLAIR PHARMA FRANCE HOLDING operate?

SINCLAIR PHARMA FRANCE HOLDING operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.